Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Ferris, Robert L and Even, Caroline and Haddad, Robert and Tahara, Makoto and Goswami, Trishna and Franks, April and Emeribe, Ugochi and Jarkowski, Anthony and Melillo, Giovanni and Licitra, Lisa (2015) Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle. Journal for ImmunoTherapy of Cancer, 3 (S2).

Preview	PDF Published Version Available under License : See the attached license file. Download (393kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Ferris, Robert L rlf1@pitt.edu RLF1 Even, Caroline Haddad, Robert Tahara, Makoto Goswami, Trishna Franks, April Emeribe, Ugochi Jarkowski, Anthony Melillo, Giovanni Licitra, Lisa
Centers:	Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date:	December 2015
Date Type:	Publication
Journal or Publication Title:	Journal for ImmunoTherapy of Cancer
Volume:	3
Number:	S2
Publisher:	BMJ
DOI or Unique Handle:	10.1186/2051-1426-3-s2-p150
Schools and Programs:	School of Medicine > Immunology School of Medicine > Otolaryngology
Refereed:	Yes
Date Deposited:	09 Aug 2016 20:12
Last Modified:	05 Aug 2020 00:55
URI:	http://d-scholarship.pitt.edu/id/eprint/29049

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item